by October Gallery
(Reuters) – Novartis AG’s gene therapy for blindness, Luxturna, is recommended for use on England’s public health service, the country’s healthcare cost-effectiveness watchdog NICE said on Tuesday. Novartis owns the…
FILE PHOTO: The logo of Swiss drugmaker Roche at its headquarters in Basel, Switzerland, February 1, 2018. REUTERS/Arnd Wiegmann/File Photo ZURICH (Reuters) – Roche Holding (ROG.S) and Spark Therapeutics (ONCE.O)…
ZURICH (Reuters) – Swiss drugmaker Novartis on Friday stepped up its challenge to Roche’s multiple sclerosis franchise, highlighting study results for its MS hopeful ofatumumab that could compete with its…
(Reuters) – GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the…
GENEVA (Reuters) – Microplastics contained in drinking water pose a “low” risk to human health at current levels, but more research is needed to reassure consumers, the World Health Organization…
VIENNA (Reuters) – An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from…
WASHINGTON (Reuters) – Genetic research that reconstructed the past population dynamics of the cave bear, a prominent prehistoric denizen of Europe, implicates Homo sapiens rather than climate cooling in the…
FILE PHOTO: The logo of Swiss pharmaceutical company Roche is seen outside the Shanghai Roche Pharmaceutical Co. Ltd. headquarters in Shanghai May 22, 2014. REUTERS/Aly Song (Reuters) – The U.S.…
VIENNA (Reuters) – An unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shares less than three weeks before the U.S. Food and Drug Administration (FDA) announced data from…
FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann (Reuters) – Roche Holding AG has priced its personalized…